SMMT
Summit Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.61
+2.77%Sep 4, 2026, 15:53 UTC
Summit Therapeutics stock jumped 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
Source:Sep 2, 2026, 21:41 UTC
Akeso Inc. announced positive overall survival results from the Phase III HARMONi-2 study, showing ivonescimab monotherapy significantly improved OS versus pembrolizumab in PD-L1-positive advanced NSCLC.
Aug 25, 2026, 22:00 UTC
Akeso Inc. announced positive topline results from the Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy in advanced biliary tract cancer, showing statistically significant overall survival benefit versus durvalumab plus chemotherapy.
Aug 25, 2026, 16:33 UTC
Summit Therapeutics announced that The Lancet Oncology published primary analysis results from its global Phase 3 HARMONi trial, showing that its drug ivonescimab combined with chemotherapy extends progression-free survival in lung cancer patients.
Source:Aug 5, 2026, 12:28 UTC
On August 5, 2026, Akeso announced that its overseas partner Summit Therapeutics will initiate a global Phase II/III clinical study (HARMONi-GU1/AK112-3008) combining ivonescimab with enfortumab vedotin for first-line treatment of locally advanced or metastatic urothelial carcinoma, with Akeso leading the China portion and Summit leading overseas portions.
Source:Jul 31, 2026, 17:22 UTC
The FDA is reviewing Summit Therapeutics' Biologics License Application for ivonescimab, with a decision expected by November 14, 2026.
Source:Jul 24, 2026, 15:53 UTC
Summit Therapeutics raised $230.8 million in gross proceeds through its ATM facility in Q2 2026 and an additional $68.4 million after the quarter.
Source:Jul 24, 2026, 02:40 UTC
Summit Therapeutics Inc. held its Q2 2026 earnings call.
Source:Jul 22, 2026, 20:30 UTC
Arcus Biosciences and Summit Therapeutics entered into a clinical trial collaboration to evaluate casdatifan combined with ivonescimab in kidney cancer.
Source:Jul 22, 2026, 11:56 UTC
Summit Therapeutics released updated overall survival results from its Phase III HARMONi clinical trial evaluating ivonescimab plus chemotherapy for non-small cell lung cancer.
Jul 14, 2026, 11:00 UTC
Summit Therapeutics signed an agreement to sell its Phase III asset ridinilazole to Biossil, Inc.
Source:Jun 11, 2026, 00:00 UTC
Summit Therapeutics canceled its planned $500 million secondary share offering one day after announcing it, citing market conditions.
Source:May 31, 2026, 12:00 UTC
Akeso and Summit Therapeutics presented positive Phase 3 trial results for their experimental lung cancer drug ivonescimab at the American Society of Clinical Oncology annual meeting.